EGFR and neoplasm: In addition, the increasing use of circulating tumor DNA in blood to clarify resistance mechanisms may favor the reporting of amplification of mutated EGFR, because the inevitable contamination by nonmalignant cells hinders clinicians from accurately analyzing the copy numbers of wild‐type genes.31